Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Mississippi.
The University of Queensland Centre for Clinical Research and Perinatal Research Centre, The University of Queensland, Brisbane, Queensland, Australia.
Am J Physiol Heart Circ Physiol. 2021 May 1;320(5):H1923-H1934. doi: 10.1152/ajpheart.00033.2021. Epub 2021 Mar 19.
Stimulation of soluble guanylate cyclase (sGC) improves fetal growth at gestational in the reduced uterine perfusion pressure (RUPP) rat model of placental ischemia suggesting a role for sGC in the etiology of intrauterine growth restriction (IUGR). This study tested the hypothesis that stimulation of sGC until birth attenuates asymmetric IUGR mitigating increased cardiovascular risk in offspring. Sham or RUPP surgery was performed at gestational (G14); vehicle or the sGC stimulator Riociguat (10 mg/kg/day sc) was administered G14 until birth. Birth weight was reduced in offspring from RUPP [intrauterine growth restricted (IUGR)], sGC RUPP (sGC IUGR), and sGC Sham (sGC Control) compared with Sham (Control). Crown circumference was maintained, but abdominal circumference was reduced in IUGR and sGC IUGR compared with Control indicative of asymmetrical growth. Gestational length was prolonged in sGC RUPP, and survival at birth was reduced in sGC IUGR. Probability of survival to postnatal was also significantly reduced in IUGR and sGC IUGR versus Control and in sGC IUGR versus IUGR. At 4 mo of age, blood pressure was increased in male IUGR and sGC IUGR but not male sGC Control born with symmetrical IUGR. Global longitudinal strain was increased and stroke volume was decreased in male IUGR and sGC IUGR compared with Control. Thus late gestational stimulation of sGC does not mitigate asymmetric IUGR or increased cardiovascular risk in male sGC IUGR. Furthermore, late gestational stimulation of sGC is associated with symmetrical growth restriction in sGC Control implicating contraindications in normal pregnancy. The importance of the soluble guanylate cyclase-cGMP pathway in a rat model of placental ischemia differs during critical windows of development, implicating other factors may be critical mediators of impaired fetal growth in the final stages of gestation. Moreover, increased blood pressure at 4 mo of age in male intrauterine growth restriction offspring is associated with impaired cardiac function including an increase in global longitudinal strain in conjunction with a decrease in stroke volume, ejection fraction, and cardiac output.
可溶性鸟苷酸环化酶(sGC)的刺激可改善宫内生长受限(IUGR)的胎盘缺血 RUPP 大鼠模型中的胎儿生长,提示 sGC 在宫内生长受限(IUGR)的发病机制中起作用。本研究测试了以下假设:在出生前刺激 sGC 可减轻不对称 IUGR,并减轻后代的心血管风险增加。在妊娠 14 天(G14)时进行假手术或 RUPP 手术;从 G14 开始,给予载体或 sGC 刺激剂 Riociguat(10mg/kg/天 sc)。与 Sham(Control)相比,RUPP 出生的后代体重减轻[宫内生长受限(IUGR)],sGC RUPP(sGC IUGR)和 sGC Sham(sGC Control)。虽然头围保持不变,但 IUGR 和 sGC IUGR 的腹围减小,表明生长不对称。sGC RUPP 的妊娠期延长,sGC IUGR 的出生存活率降低。与 Control 相比,IUGR 和 sGC IUGR 以及 sGC IUGR 与 IUGR 相比,出生后到 4 个月的存活率也显著降低。在 4 个月龄时,IUGR 和 sGC IUGR 雄性的血压升高,但具有对称 IUGR 的 sGC 雄性的血压没有升高。与 Control 相比,IUGR 和 sGC IUGR 的男性的整体纵向应变增加,而每搏量减少。因此,晚期妊娠 sGC 的刺激不能减轻雄性 sGC IUGR 的不对称 IUGR 或增加心血管风险。此外,sGC 晚期妊娠刺激与 sGC Control 的对称生长受限有关,这暗示了在正常妊娠中存在禁忌症。可溶性鸟苷酸环化酶-cGMP 途径在胎盘缺血大鼠模型中的重要性在发育的关键窗口期间不同,这暗示其他因素可能是妊娠末期胎儿生长受损的重要介质。此外,4 月龄时 IUGR 雄性后代的血压升高与心脏功能受损有关,包括整体纵向应变增加,同时每搏量、射血分数和心输出量减少。